Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
119 hedge funds and large institutions have $1.1B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 8 closing their positions.
513% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $2.04M
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
17% more funds holding
Funds holding: 102 → 119 (+17)
8% less capital invested
Capital invested by funds: $1.19B → $1.1B (-$91.1M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCIM
TIAA CREF Investment Management
New York
|
+$14.8M |
| 2 |
SC
Samlyn Capital
New York
|
+$11.3M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.73M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$7.36M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$6.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$64.5M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$22.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$7.96M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.2M |
BHVN Hedge Fund Activity: Q3 2018 in Review
119 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2018, worth a combined $1.1B — down 7.6% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BHVN positions and 8 closed out — a net gain of 17 holders — while 45 added to existing stakes and 36 trimmed.
The largest buyer was TIAA CREF Investment Management, adding an estimated $14.8M. The largest seller was Perceptive Advisors, cutting an estimated $64.5M.
- 119 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2018, up from 102 in Q2 2018.
- Funds reported $1.1B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2018, down 7.6% quarter-over-quarter.
- 25 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2018 and 8 closed out, a net change of +17 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2018 was TIAA CREF Investment Management, an estimated $14.8M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2018 was Perceptive Advisors, an estimated $64.5M sold.
Based on aggregated 13F filings for Q3 2018.